Helen E. Davies

Helen E. Davies

Auto-generated profile, based on publicly available information

Helen E. Davies

Cardiff and Vale University Health Board

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
APAmy D. Proal
Amy D. Proal
MVMichael B. VanElzakker
Michael B. VanElzakker
SASoo Aleman
Soo Aleman
KBKatie Bach
Katie Bach
Brittany Phatana BoribongBrittany Phatana Boribong
Brittany Phatana Boribong
EWE. John Wherry
E. John Wherry
Millions of people are suffering from Long COVID or post-acute sequelae of COVID-19 (PASC). Several biological factors have emerged as potential drivers of PASC pathology. Some individuals with PASC may not fully clear the coronavirus SARS-CoV-2 after acute infection. Instead, replicating virus and/or viral RNA—potentially capable of being translated to produce viral proteins—persist in tissue as a ‘reservoir’. This reservoir could modulate host immune responses or release viral proteins into the circulation. Here we review studies that have identified SARS-CoV-2 RNA/protein or immune responses indicative of a SARS-CoV-2 reservoir in PASC samples. Mechanisms by which a SARS-CoV-2 reservoir may contribute to PASC pathology, including coagulation, microbiome and neuroimmune abnormalities, are delineated. We identify research priorities to guide the further study of a SARS-CoV-2 reservoir in PASC, with the goal that clinical trials of antivirals or other therapeutics with potential to clear a SARS-CoV-2 reservoir are accelerated.

15 February 2024 in Med
Verified
Journal Article
Open access
KBKirsten Baillie
Kirsten Baillie
HDHelen E. Davies
Helen E. Davies
SKSamuel B.K. Keat
Samuel B.K. Keat
KLKristin Ladell
Kristin Ladell
KMKelly L. Miners
Kelly L. Miners
WZWioleta M. Zelek
Wioleta M. Zelek
Long COVID encompasses a heterogeneous set of ongoing symptoms that affect many individuals after recovery from infection with SARS-CoV-2. The underlying biological mechanisms nonetheless remain obscure, precluding accurate diagnosis and effective intervention. Complement dysregulation is a hallmark of acute COVID-19 but has not been investigated as a potential determinant of long COVID. We quantified a series of complement proteins, including markers of activation and regulation, in plasma samples from healthy convalescent individuals with a confirmed history of infection with SARS-CoV-2 and age/ethnicity/sex/infection/vaccine-matched patients with long COVID. Markers of classical (C1s-C1INH complex), alternative (Ba, iC3b), and terminal pathway (C5a, TCC) activation were significantly elevated in patients with long COVID. These markers in combination had a receiver operating characteristic predictive power of 0.794. Other complement proteins and regulators were also quantitatively different between healthy convalescent individuals and patients with long COVID. Generalized linear modeling further revealed that a clinically tractable combination of just four of these markers, namely the activation fragments iC3b, TCC, Ba, and C5a, had a predictive power of 0.785. These findings suggest that complement biomarkers could facilitate the diagnosis of long COVID and further suggest that currently available inhibitors of complement activation could be used to treat long COVID. This work was funded by the National Institute for Health Research (COV-LT2-0041), the PolyBio Research Foundation, and the UK Dementia Research Institute.

30 April 2025 in Nature Immunology
Verified
Journal Article
Open access
PDF file
YGYu Gao
Yu Gao
CCCurtis Cai
Curtis Cai
SASarah Adamo
Sarah Adamo
EBElsa Biteus
Elsa Biteus
HKHabiba Kamal
Habiba Kamal
DPDavid A. Price
David A. Price
Long coronavirus disease (COVID) is a heterogeneous clinical condition of uncertain etiology triggered by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we used ultrasensitive approaches to profile the immune system and the plasma proteome in healthy convalescent individuals and individuals with long COVID, spanning geographically independent cohorts from Sweden and the United Kingdom. Symptomatic disease was not consistently associated with quantitative differences in immune cell lineage composition or antiviral T cell immunity. Healthy convalescent individuals nonetheless exhibited higher titers of neutralizing antibodies against SARS-CoV-2 than individuals with long COVID, and extensive phenotypic analyses revealed a subtle increase in the expression of some co-inhibitory receptors, most notably PD-1 and TIM-3, among SARS-CoV-2 nonspike-specific CD8+ T cells in individuals with long COVID. We further identified a shared plasma biomarker signature of disease linking breathlessness with apoptotic inflammatory networks centered on various proteins, including CCL3, CD40, IKBKG, IL-18 and IRAK1, and dysregulated pathways associated with cell cycle progression, lung injury and platelet activation, which could potentially inform the diagnosis and treatment of long COVID.

18 September 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
APAmy D. Proal
Amy D. Proal
MVMichael B. VanElzakker
Michael B. VanElzakker
SASoo Aleman
Soo Aleman
KBKatie Bach
Katie Bach
Brittany Phatana BoribongBrittany Phatana Boribong
Brittany Phatana Boribong
EWE. John Wherry
E. John Wherry

28 January 2026 in Thorax
Verified
Journal Article
Open access
EMEleanor K Mishra
Eleanor K Mishra
HDHelen Davies
Helen Davies
SASyed Hamza Abbas
Syed Hamza Abbas
CHCheryl Hardy
Cheryl Hardy
DBDominic T Beith
Dominic T Beith
NRNajib M Rahman
Najib M Rahman
Introduction: In patients with malignant pleural effusions (MPE), pleural fluid reaccumulates at variable rates following therapeutic aspiration. The aim of this study was to identify variables which predict time to next procedure and use them to develop a predictive score. Methods: This prospective observational cohort study in 10 British hospitals recruited patients with known or suspected malignant effusions undergoing therapeutic aspiration. Follow-up lasted 3 months and assessed time to next clinically indicated pleural procedure. Regression analysis was performed to identify independent variables predicting time to next procedure, and a score derived. Initial validation was done in two external cohorts. Measurements and main results: 241 patients were recruited. Within the derivation cohort (n=180), baseline respiratory rate (R), pleural effusion depth on ultrasound (E) and dyspnoea measured using a visual analogue scale (D) (combined to form the RED score) were independent predictors of time to next procedure. Predictive models provided areas under the receiver operator curve of 0.73 and 0.75. Initial validity testing in two cohorts (n=31, n=57) demonstrated reasonable predictive value. Conclusions: In patients with MPE, baseline respiratory rate, pleural effusion depth on ultrasound and dyspnoea predict time to next procedure. Trial registration number: ISRCTN16567838 .

6 November 2025 in Health Expectations
Verified
Journal Article
Open access
CLCassie Lee
Cassie Lee
PWPaul Williams
Paul Williams
AAAmiad Abrahams
Amiad Abrahams
JDJulie Lorraine Darbyshire
Julie Lorraine Darbyshire
HDHelen E. Davies
Helen E. Davies
SESarah Elkin
Sarah Elkin
Background: Long Covid (LC) is associated with long‐term health impacts that require ongoing support from healthcare services. We aimed to gain insights into patients' perceptions of their ongoing symptoms of LC, the effect on daily living and vocation, perceptions of what helps with LC recovery, as well as LC care pathways and ongoing care needs. Methods: An online survey was sent to 513 participants who had used one of three LC services across England and Wales between 2020 and 2024. Participants were invited to share their experiences. We employed a mixed‐methods approach for data analysis, synthesising findings from quantitative and qualitative data. All data shared between sites was de‐identified. Results: 269 (52.4%) participants completed the survey. The mean age was 52.7 (sd ± 12.0), 69.1% female and 55.0% were White‐British. The mean duration since initial SARS‐CoV‐2 infection was over 3 years (1204.4 ± 275.7 days). The Post‐Covid Functional Status (PCFS) scale indicated that most participants (94.1%, n = 253) had not fully recovered. When employing a global rate of change scale, 39.0% ( n = 96) of 246 responders indicated they are still making improvements with respect to their recovery; 40.7% ( n = 100) had plateaued, and 20.3% ( n = 50) reported a worsening trajectory. Those with ongoing symptoms described fatigue 83.0% ( n = 210), cognitive dysfunction 58.5% ( n = 148) and breathlessness or wheezing 43.9% ( n = 111) most frequently. Of those who responded, 20.8% ( n = 48) were ‘working as prior to their initial LC infection’ and 25.5% ( n = 59) were currently ‘unable to work’. Almost half (44.3%; n = 86) were no longer receiving care whilst also reporting unmet care needs. In total, 62.7% ( n = 126) of participants indicated unmet care needs, and qualitative analysis indicated five overarching domains as having an important impact on long‐term LC recovery and ongoing healthcare needs. These were Living with LC, LC interventions and recovery, Approach to the delivery of care, Insufficient support and Suggestions and improvement. Conclusion: This study indicates the extent to which individuals continue to experience ongoing symptoms of LC, including aspects related to recovery and vocational impact, highlighting the potential widening gap between the ongoing need to support those living with LC and the limited provision of care. Patient or Public Contribution: The survey was co‐produced with Experts by Experience, who had previously attended an LC service and members of the Patient Advisory Group within the Locomotion Consortium. Collaboration and involvement continued throughout the study, including analysis, interpretation and writing processes. Clinical Trial Registration: Study registration details are available at ClinicalTrials.gov : NCT05057260 and ISRCTN: 15022307.